LEO Pharma supports the FDA’s selection of psoriasis as a priority disease

LEO Pharma supports the recent decision by the U.S. Food and Drug Administration (FDA) to include psoriasis as one of eight priority disease areas in its 2016-2017 Patient Focused Drug Development Initiative.i  Psoriasis is an autoimmune disease that has a major impact on patients’ lives and subsequent comorbidities, affecting 7.5 million people in the US alone.ii

Parsipanny, NJ, 29 July 2015 – As part of LEO Pharma’s ongoing commitment to supporting patients living with psoriasis, LEO Pharma along with the National Psoriasis Foundation (NPF) and other stakeholders, worked through the FDA’s commenting process to ensure psoriasis was included in the Patient Focused Drug Development Initiative.iii  

“We applaud the FDA for including psoriasis in the priority disease area and believe it is a major milestone for psoriasis patients in the United States as it will raise awareness regarding patient needs,” said Barbara Osborne, President and CEO of LEO Pharma Inc. in the U.S.  “As a company dedicated to improving the lives of patients living with skin diseases, including psoriasis, we are proud to have been a valuable partner throughout the information gathering process.” 

In October 2014, the FDA published a preliminary listiv of 16 disease areas for consideration for the initiative, and asked the public to determine the disease areas of greatest priority. As a patient-centric dermatological company, LEO Pharma participated in this commenting process in raising the awareness of psoriasis – a disease which was not originally part of the FDA's list. 

LEO Pharma will attend a future public meeting hosted by the FDA to discuss psoriasis, its impact on patients' daily lives, the types of treatments available for patients, and patients' perspectives on the acceptability of available therapies.  The public meeting is also a unique opportunity for psoriasis patients to have their voices heard concerning their experiences and perspectives of living with and treatment of a chronic remitting and relapsing disease.   

About Psoriasisv 

Psoriasis is a chronic, inflammatory disease, which is frequently accompanied by multiple physical and/or psychological comorbidities, such as metabolic syndrome and psoriatic arthritis.

Plaque psoriasis is estimated to affect about 2-4% of the population in the US. Eighty percent (80%) of patients are affected by plaque psoriasis – the most common clinical form of psoriasis. 

References 

i    https://www.federalregister.gov/articles/2015/07/02/2015-16359/prescription-drug-user-fee-act-patient-focused-drug-development-announcement-of-disease-areas-for
ii   https://www.psoriasis.org/cure_known_statistics
iii  http://www.fda.gov/ForIndustry/UserFees/PrescriptionDrugUserFee/ucm347317.htm
iv  https://www.federalregister.gov/articles/2014/10/08/2014-23965/prescription-drug-user-fee-act-patient-focused-drug-development-request-for-comments
v   Parisi R, et al. Global Epidemiology of Psoriasis: A Systematic Review of Incidence and Prevalence. The Society for Investigative Dermatology. J Invest Dermatol 2013;133(2):377-85

We use cookies on this website

The cookies help us gain a better understanding of how you use our website; display applications and functionalities, to optimise your website experience, to assign a unique identification number to you, and to help you remember your user ID and password when you return to the website. We also use cookies to generate statistical information.

By continuing to browse our website, you are agreeing to our use of cookies

If you want to know more about our cookie policy and how to avoid and delete cookies click here.